Investors

Meda’s acquistion of Rottapharm Madaus completed

On July 31, Meda announced the acquisition of Italian Rottapharm. With the acquisition, Meda becomes a leading European specialty pharma company with pro forma revenues of more than 18 billion in 2013. The combined entity will have enhanced scale, broader geographical presence and dispose of a product portfolio that is well balanced between Rx and Cx / OTC. Cost synergies for the combined entity is estimated to  SEK 900 million, with full effect in 2016.

Below aggregated, published information about the whole acquisition – links.

Meda EGM, Thursday November 6th at 1 pm

This website is intended for people seeking information on Meda AB's Global operations.
We also have national marketing sites. Links to these are under Meda Worldwide at the top of the page.